Press release

Vifor Fresenius Medical Care Renal Pharma enters into partnership with Relypsa to commercialise Patiromer FOS

Tuesday, 11 August 2015, ↓ directly to download

Vifor Fresenius Medical Care Renal Pharma enters into partnership with Relypsa to commercialise Patiromer FOS

Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a common company of Galenica and Fresenius Medical Care, and Relypsa, Inc. have entered into an exclusive partnership to commercialise the potassium binder Patiromer for Oral Suspension (Patiromer FOS) in Europe and additional territories. Patiromer FOS is an investigational drug of Relypsa for the treatment of hyperkalaemia that occurs most frequently in chronic kidney disease and heart failure patients. It represents an ideal complement to the existing product portfolio of VFMCRP for patients with chronic kidney disease and iron deficiency.

Read more

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).

Contact

Christina Hertig

Christina Hertig

Head of Corporate Communications


Galenica Ltd.

Corp. Communications
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 85 17
Fax:
+41 58 852 85 58

Julien Vignot

Julien Vignot

Head Investor Relations


Galenica Ltd.

Investor Relations
Untermattweg 8
CH-3027 Bern

Phone:
+41 58 852 81 11
Fax:
+41 58 852 81 12

Send link

Send as link



Links